In September 2023, BTM signed exclusive rights to commercialize BTM101 in Mainland China，Hong Kong and Macao, entering into the field of Medical Aesthetic.
On 28 April 2023, an Investigational New Drug application for BTM002 was approved by the National Medical Products Administration of China (the "NMPA")
BTM signed esxclusive rights to commercialize new three products in China, supplement its Orthopedic product portfolio and entering the treatment in rare disease
Launched Pellefeel mask pressure relief pad in China, CR Pharma Shanghai acts as the general distributor
BTM signed the exclusive rights to promote Pellefeel & PLTenus in China, entering the field of Orthopedics and Wound Care